Assistive Robotics Market By Robot Type (Physically Assistive Robots, Socially Assistive Robots); By Application (Rehabilitation Assistance, Mobility Assistance, Elderly Assistance, Daily Living Assistance, Cognitive and Social Support); By End User (Hospitals and Rehabilitation Centers, Home Care Settings, Elderly Care Facilities, Individuals and Caregivers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Assistive Robotics Market: From Clinical Rehabilitation to Everyday Mobility and Independent Living  – (Updated On: 20-Aug-2026)

The Global Assistive Robotics Market was valued at USD 3.45 billion in 2025 and is projected to reach USD 8.42 billion by 2032, growing at a CAGR of 13.6% during 2026–2032.

 

Assistive Robots Advance Through Narrower, Evidence-Based Use Cases

The assistive robotics market is moving away from general-purpose promises toward devices designed for a specific mobility, rehabilitation or daily-living task. Regulatory pathway, user fit and caregiver workflow now shape commercial success as much as robotics performance.

FDA's Breakthrough Devices framework remains relevant for qualifying devices, while the VIGX P6 illustrates consumer interest in terrain-adaptive camera-assisted exoskeletons. The latter is secondary reporting and should not be treated as clinical validation.

Product precision should separate powered exoskeletons, robotic wheelchairs, feeding aids, transfer systems and rehabilitation robots. Load, range, donning time, gait mode, fall protection, user eligibility, supervision and software updates are critical.

Hospitals need evidence and service coverage; consumers need comfort, price and simple controls. Reimbursement remains fragmented, so manufacturers may need leasing and institutional channels.

Regional adoption will not be uniform. Local standards, distribution depth, operating conditions and buyer economics determine whether the same product is treated as a premium upgrade, a compliance requirement or an impractical alternative. Companies should therefore build geographic assumptions from verified route-to-market evidence and installed-use conditions, not transfer one launch announcement across every country.

For decision-makers, the practical test is whether a supplier can document performance under the exact operating conditions, maintain consistent availability and support the product after installation or launch. Price comparisons should be normalized for configuration, service content, qualification burden and lifecycle risk rather than reduced to an unsupported unit-cost claim. This also provides a clearer basis for comparing established suppliers with newer entrants.

For the assistive robotics market, that evidence threshold is important because application fit, documentation and execution quality can change the commercial outcome even when the underlying category appears mature. Evaluation should test these variables against named products and operating results.

SMR Technology Perspective: The market should grow through defined populations and measured outcomes. Suppliers that combine human-factors design with clinical support will progress faster than those leading with autonomy alone.

 

Assistive robotics is a technology field that develops intelligent machines designed to help people with physical, sensory, or cognitive limitations. These robots work alongside humans to improve independence, safety, and quality of life, especially in healthcare, rehabilitation, and daily activities.

 

Assistive robots are mainly used to restore movement, support personal care, assist recovery, and provide emotional support. Exoskeletons and wearable robotic systems help individuals with spinal cord injuries or stroke regain walking ability. Robotic arms and home assistance devices help users perform daily tasks such as eating, bathing, and moving independently. Rehabilitation robots guide patients through repeated therapy exercises to improve strength and mobility. Socially assistive robots provide companionship, support children with autism in developing social skills, and reduce loneliness among older adults. They also help reduce the physical and emotional burden on caregivers.

 

The assistive robotics industry is expanding with advancements in surgical systems, rehabilitation devices, and automated healthcare solutions. Recent developments include Johnson & Johnson’s OTTAVA robotic surgical system for soft tissue procedures, Medtronic’s Stealth AXiS and Hugo robotic platforms for advanced surgical assistance, Momentis Surgical’s Anovo system for multiple surgical approaches, and LEM Surgical’s humanoid robot for spinal procedures. In patient care, Wandercraft Atalante X uses AI-powered exoskeleton technology to improve mobility, Aletta automates blood collection using imaging guidance, and iotaMotion iotaSOFT provides robotic precision for cochlear implant procedures. These innovations are making healthcare more efficient, accurate, and accessible.

 

Rising disability prevalence, rapid population aging, and growing pressure on healthcare systems are accelerating demand for assistive robotics solutions. With more than 1.3 billion people worldwide living with disabilities and the global population aged 60+ expected to exceed 2 billion by 2050, technologies such as robotic exoskeletons, rehabilitation robots, and intelligent care assistants are becoming increasingly important. Furthermore, healthcare workforce shortages projected to reach 10 million workers by 2030 are encouraging adoption of robotic systems that enhance patient independence, support caregivers, and improve rehabilitation outcomes.

 

How Large Is the Population Need Supporting Demand for Assistive Robots?

The underlying population need for assistive technologies is large, but not all of it directly translates into demand for robotics. The World Health Organization estimates that more than 2.5 billion people currently need at least one assistive product, rising to over 3.5 billion by 2050 as ageing and chronic disease increase. However, this figure includes a wide range of non-robotic aids (such as hearing aids, mobility aids, and basic support devices), so only a subset represents potential demand for assistive robotics. WHO also notes that about two-thirds of people aged 60+ require at least one assistive product, but access gaps remain significant, with some countries meeting only a small fraction of total need.

Ageing is a key long-term driver, but again it does not automatically convert into robotics adoption. The United Nations projects that one in six people globally will be aged 65 or older by 2050, increasing demand for mobility support, rehabilitation, and independent living solutions. Within this group, assistive robotics is most relevant for individuals with higher levels of functional limitation or rehabilitation needs rather than the broader ageing population.

In the United States, disability prevalence helps illustrate the potential user base more concretely. CDC data show that 28.7% of adults report some form of functional disability, including mobility (12.2%), cognitive (13.9%), independent living (7.7%), and self-care (3.6%) limitations. While not all of these individuals are candidates for robotics, they represent the broader pool from which demand for mobility assistance, rehabilitation robotics, and home-support systems may emerge.

 

What Are the Key Ways Assistive Robotics Is Classified Across Its Core Uses and Users?

The Dual Engine of Assistive Robotics: Physical Power vs Social Intelligence

Physically Assistive Robots accounted for 62.0% of the market, valued at USD 2.14 billion in 2025, and are projected to grow at a CAGR of 12.7%. Their leading position reflects established use of powered exoskeletons, robotic rehabilitation systems, mobility-support devices, and robotic arms across hospitals, rehabilitation centers, and selected home-care settings.

Socially Assistive Robots represented 38.0% of the market, equivalent to USD 1.31 billion in 2025, and are expected to expand at a faster CAGR of 15.0%. Growth is supported by increasing interest in cognitive assistance, companionship, reminders, behavioral support, and interactive care for older adults and people requiring greater everyday assistance.

 

Mapping Human Need to Robotic Support: Key Application Domains

Rehabilitation Assistance was the largest application segment with a 30.0% share and USD 1.04 billion in 2025, growing at a CAGR of 12.4%. Hospitals and specialist rehabilitation centers continue to use robotic systems for gait, balance, and upper-limb therapy, particularly for patients recovering from stroke, spinal cord injury, and other neurological conditions.

Mobility Assistance accounted for 24.0% of the market and USD 828.0 million in 2025, with a projected CAGR of 13.1%. Powered exoskeletons, intelligent mobility devices, and robotic walking support are gaining commercial relevance as reimbursement pathways improve and manufacturers extend products from supervised clinical environments into personal use.

Elderly Assistance represented a 19.0% share, valued at USD 655.5 million in 2025, and is forecast to grow at the fastest application CAGR of 15.3%. Ageing populations are increasing interest in robots that support mobility, reminders, social interaction, and everyday independence while helping care organizations manage growing workforce pressure.

Daily Living Assistance held 16.0% of the market, or USD 552.0 million in 2025, and is expected to grow at a CAGR of 13.4%. Robotic arms, home-support systems, and personal assistance devices address activities such as object handling and other routine tasks for users with significant motor limitations.

Cognitive and Social Support accounted for 11.0% of the market and USD 379.5 million in 2025, with a projected CAGR of 15.0%. Demand is developing around interactive robots that provide communication, reminders, engagement, and behavioral support, particularly within dementia care, elderly care, and other settings where continuous human assistance may be difficult to provide.

 

From Clinical Floors to Living Rooms: Who Actually Uses Assistive Robotics

Hospitals and Rehabilitation Centers were the largest end-user segment, accounting for 35.0% of the market and USD 1.21 billion in 2025, with a CAGR of 11.9%. Their leading share reflects the concentration of high-value rehabilitation robots and clinical exoskeletons in facilities that have trained therapists, established rehabilitation programs, and the capacity to support capital-equipment purchases.

Home Care Settings represented 30.0% of the market, valued at USD 1.04 billion in 2025, and are projected to grow at the fastest end-user CAGR of 14.9%. Greater availability of personal mobility robots, reimbursement development, ageing-in-place preferences, and demand for assistance outside institutional settings are widening the commercial opportunity for home-based systems.

Elderly Care Facilities accounted for 20.0% of the market and USD 690.0 million in 2025, with a projected CAGR of 14.1%. These facilities are increasingly relevant for socially assistive, mobility-support, and rehabilitation robots as operators look for ways to support residents while addressing persistent caregiver workload pressures.

Individuals and Caregivers represented 15.0% of the market, equivalent to USD 517.5 million in 2025, and are expected to grow at a CAGR of 14.0%. Expansion in personal exoskeletons, robotic arms, and home-assistance technologies is gradually increasing direct use, although affordability, reimbursement eligibility, and support requirements continue to influence adoption.

 

Why Are Physical and Mobility Assistance Robots Becoming a Major Commercial Segment?

Physical-assistance robots represent one of the most commercially defined segments because they address clear functional limitations such as walking, standing, grasping, and navigation. This category includes powered exoskeletons, robotic arms, and smart mobility devices. However, commercial adoption depends less on technical capability alone and more on whether these systems can be reliably used in clinical workflows or daily life, and whether they are financially accessible.

A more specific demand base exists in conditions such as spinal cord injury. The 2026 National Spinal Cord Injury Statistical Center data sheet estimates around 311,560 people living with traumatic spinal cord injury in the U.S., with approximately 18,482 new cases annually. This group represents a primary target for home-use exoskeletons such as ReWalk and Ekso Indego Personal, rather than the broader disability population.

Commercial viability is also increasingly shaped by reimbursement. CMS established a Medicare payment level of USD 91,031.93 for HCPCS code K1007 (2024) for qualifying powered lower-extremity exoskeletons. While this does not guarantee coverage for all patients, it creates a structured pathway that reduces reliance on full out-of-pocket purchases and supports adoption through durable medical equipment channels.

 

Why Is Rehabilitation Robotics Becoming More Closely Tied to Clinical and Economic Evidence?

Rehabilitation robotics is primarily used in clinical settings to deliver repetitive, high-intensity therapy for gait, balance, and upper-limb recovery. The demand base is significant, particularly in stroke rehabilitation. CDC estimates that more than 795,000 people experience a stroke annually in the U.S., including around 610,000 first-time strokes. These patients form a key target group for robotic rehabilitation systems.

However, clinical adoption is increasingly constrained by evidence requirements. NICE guidance in England (2023) recommends not routinely offering robot-assisted arm training in stroke rehabilitation due to insufficient evidence of superior functional outcomes compared with conventional physiotherapy at similar intensity, alongside cost-effectiveness concerns. This does not eliminate robotics from rehabilitation, but it limits automatic adoption and requires stronger proof of added value.

As a result, purchasing decisions in hospitals are shifting away from automation alone toward measurable clinical impact—such as improved outcomes, increased therapy capacity, reduced staff burden, or better documentation of progress.

 

How Are Cognitive and Socially Assistive Robots Expanding the Addressable Need?

Socially assistive robots target a different type of need: support for cognition, behavior, communication, and daily routines rather than physical movement. These systems are used in contexts such as elder care, dementia support, developmental assistance, and independent living support.

Dementia is a major driver of this segment. WHO estimates that 57 million people were living with dementia in 2021, with nearly 10 million new cases annually. The condition also creates a large care burden, with significant reliance on informal caregivers. This has led to interest in companion robots, reminder systems, and interactive assistants that can supplement—not replace—human care.

Unlike medical rehabilitation robots, many socially assistive systems are not strictly regulated as medical devices unless they make therapeutic claims. This creates a more fragmented market, where adoption depends heavily on user acceptance, privacy considerations, and perceived usefulness rather than clinical reimbursement pathways.

 

Which Companies Are Shaping Competition in the Assistive Robotics Market?

Competition is developing across several business models. Some companies sell expensive institutional rehabilitation equipment, some concentrate on personal exoskeletons, and others combine medical robotics with broader rehabilitation portfolios. Revenue therefore depends not only on unit sales but also on service, maintenance, leasing, reimbursement relationships and clinical distribution.

DIH Holding and Hocoma’s Position in Rehabilitation Robotics Market

DIH Holding US is focused on robotic and technology-supported physical rehabilitation, with its Hocoma portfolio covering different stages of neurological recovery. Products include Lokomat for robot-assisted gait training, Armeo systems for upper-limb rehabilitation, Andago for overground walking support, Erigo for early mobilization and C-Mill systems for gait and balance training.

DIH reported USD 62.9 million in revenue for the fiscal year ended March 31, 2025. Its filing states that Lokomat represented more than 45% of revenue, highlighting how strongly the company's commercial position remains linked to robotic gait rehabilitation. DIH also reported approximately 1,219 Lokomat installations across more than 650 facilities worldwide, giving it one of the more established clinical installed bases in this segment.

 

Ekso Bionics Combines Clinical Rehabilitation with Personal Mobility

Ekso Bionics operates across both institutional and personal exoskeleton markets. Its healthcare portfolio includes EksoNR, Ekso Indego Therapy and Ekso Indego Personal, while its Enterprise Health business targets rehabilitation centers treating stroke, traumatic brain injury, multiple sclerosis and spinal cord injury.

The company's first-quarter 2026 revenue was approximately USD 2.14 million, with device revenue representing USD 1.34 million. Ekso's longer-term commercial opportunity increasingly depends on converting Medicare coverage into repeatable personal-device sales while continuing to sell capital equipment to rehabilitation facilities. The company has expanded relationships with durable medical equipment and orthotics providers to support that reimbursement-driven channel.

 

Lifeward’s Reimbursement-Driven Mobility Portfolio

Lifeward operates the ReWalk Personal Exoskeleton, ReWalk Rehabilitation platform, ReStore, AlterG Anti-Gravity systems and MyoCycle products. The company therefore combines personal robotic mobility with broader rehabilitation technologies rather than depending on a single device category.

Lifeward reported USD 3.9 million in revenue during the first quarter of 2026. ReWalk Personal exoskeleton revenue increased 11% year over year to USD 1.6 million, while weaker AlterG shipments reduced overall revenue. The company has identified expansion of public and commercial reimbursement for ReWalk as one of its main growth routes, supported by U.S. Medicare developments and agreements with German health insurers.

 

CYBERDYNE Uses Human-Intent Sensing to Differentiate Its Portfolio

Japan-based CYBERDYNE has built its assistive robotics strategy around the HAL platform. The portfolio includes Medical HAL Lower Limb, Medical HAL Single Joint, wellbeing versions of HAL, lumbar-support systems and supporting rehabilitation technologies.

HAL's main differentiation is its use of bio-electrical signals detected at the skin to identify the wearer's intention to move and synchronize robotic assistance with voluntary movement. CYBERDYNE is also expanding through institutional partnerships. Malaysia's PERKESO National Neuro-Robotics and Cybernics Rehabilitation Center opened in June 2026, following installation of 50 HAL sets representing 65 units completed in August 2025 under an agreement valued at approximately USD 4.6 million.

 

Wandercraft Extends Self-Balancing Robotics Beyond the Rehabilitation Center

France-based Wandercraft focuses on self-balancing robotic systems. Its assistive portfolio includes Atalante X, designed for institutional rehabilitation, and Eve, a personal exoskeleton intended to move the company's technology toward home and community use. Wandercraft says Atalante X is deployed in more than 100 inpatient and outpatient rehabilitation centers.

The company secured USD 75 million in equity and debt financing in June 2025 to support international expansion, Atalante X adoption and commercialization of its newer robotics platforms. Eve's August 2026 FDA clearance is strategically important because it expands Wandercraft's addressable opportunity from facility-based rehabilitation toward personal mobility.

 

What Factors Are Driving the Global Acceleration of Assistive Robotics Adoption Across Healthcare Systems and Aging Societies?

North America as an Important Market for Assistive Robotics

North America combines a large target population, developed rehabilitation infrastructure, active medical-device regulation and increasingly defined reimbursement mechanisms. In the U.S., 28.7% of adults report some form of functional disability, while mobility and cognitive disabilities affect 12.2% and 13.9%, respectively. More than 795,000 strokes occur annually, and approximately 311,560 Americans are living with traumatic spinal cord injury. North America accounted for a 39.0% market share, valued at USD 1.35 billion, and is projected to grow at a CAGR of 12.1%, reflecting its strong adoption of assistive robotics driven by advanced healthcare systems and reimbursement support.

 

Why Europe Is Developing Through Both Reimbursement Support and Evidence-Based Procurement

Europe has strong demographic demand for mobility and rehabilitation support. Eurostat reports that the EU had approximately 99 million people aged 65 or older in 2025, representing 22% of the population, up from 17% in 2005. The population aged 80 and above represented another 6% of the EU population. Europe accounted for a 28.0% market share, valued at USD 966.0 million, and is projected to grow at a CAGR of 13.6%, reflecting its strong adoption of assistive robotics driven by ageing demographics and advanced healthcare infrastructure.

 

Asia-Pacific as an Important Development and Deployment Region

Asia-Pacific combines some of the world's most rapidly ageing populations with strong robotics capabilities. Japan is the clearest example. According to Japan's Statistics Bureau, people aged 65 and older represented 29.4% of the country's population in 2025, the highest level recorded nationally. This demographic structure supports investment in mobility assistance, rehabilitation and technologies that reduce physical care requirements. The Asia Pacific region accounted for 22.0% of the market, valued at USD 759.0 million, and is projected to grow at a CAGR of 14.9%, reflecting its strong expansion potential in assistive robotics.

The region is also producing large institutional deployments. CYBERDYNE's collaboration with Malaysia's social security organization PERKESO has placed dozens of HAL systems into a dedicated national neuro-robotics rehabilitation center. Such projects matter because they move assistive robotics beyond individual equipment purchases toward integrated rehabilitation infrastructure.

 

Drivers of Long-Term Assistive Robotics Demand in Latin America

Latin America and the Caribbean are ageing faster than many healthcare systems are expanding their long-term care capacity. ECLAC estimates that the region had around 65.4 million people aged 65 and older in 2024, equivalent to 9.9% of the population. By 2050, this group is projected to reach approximately 138 million people and 18.9% of the population. In the assistive robotics market, Latin America accounted for a 7.0% share, valued at USD 241.5 million, and is projected to grow at a CAGR of 15.6%.

 

Assistive Robotics Opportunity Across the Middle East and Africa

The Middle East and Africa combine very high unmet assistive-technology need with substantial affordability and infrastructure constraints. WHO reported that nearly 100 million people in the Eastern Mediterranean Region need one or more assistive products, while only around one in ten has access to the products required. The region accounted for a 4.0% market share, valued at USD 138.0 million in 2025, and is projected to grow at a CAGR of 16.4%, reflecting gradual but accelerating adoption of assistive robotics despite structural access challenges.

In the WHO African Region, more than 200 million people currently need at least one assistive product, and the number is projected to double by 2050. WHO estimates that only around 15%–25% of people requiring assistive products in the region currently have access. These figures indicate a large long-term need, but they also show why market development will require broader rehabilitation infrastructure, financing mechanisms and trained personnel rather than robotics investment alone.

 

What Will Define the Next Phase of Competition in the Assistive Robotics Market?

The next phase of competition in assistive robotics will depend more on access and affordability than on technical capability alone. Companies must secure regulatory clearance, prove clinical and economic value to payers, and build strong reimbursement and service networks to support real-world use beyond hospitals and research settings.

Home-use approvals are especially important, as they expand robotics from specialist rehabilitation centers into everyday care. Recent policy moves—such as CMS reimbursement for exoskeletons in the U.S. and insurer coverage agreements in Germany (e.g., BARMER for ReWalk)—show how reimbursement decisions can significantly widen the addressable user base.

AI is also becoming a key differentiator, improving movement control, user intent detection, and personalized support. However, its value depends on solving practical needs like improving independence, reducing caregiver burden, and increasing therapy efficiency—not just adding new features.

 

Assistive Robotics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.45 Billion
Revenue Forecast in 2032	USD 8.42 Billion
Overall Growth Rate	CAGR of 13.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Robot Type, By Application, By End User, By Geography
By Robot Type	Physically Assistive Robots, Socially Assistive Robots
By Application	Rehabilitation Assistance, Mobility Assistance, Elderly Assistance, Daily Living Assistance, Cognitive and Social Support
By End User	Hospitals and Rehabilitation Centers, Home Care Settings, Elderly Care Facilities, Individuals and Caregivers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising demand for mobility and rehabilitation support among aging and disabled populationsGrowing adoption of robotic technologies to address healthcare workforce shortages and caregiver burdenAdvancements in AI-enabled movement control, human intent sensing, and personalized assistive solutions
Customization Option	Available upon request